Disappointing clinical trials and steep prices are leading some advisers to split their bets on biotech stocks between funds focused on health care and technology.

"We like to invest in companies with innovative products, but at reasonable prices. Biotech has become too rich for our tastes," says Curt Gross, research director at FAI Wealth Management in Columbia, Md., with $325 million in assets.

Market valuations...